Show simple item record

dc.contributor.authorHeseltine, J.
dc.contributor.authorAllison, Jennifer
dc.contributor.authorWong, S.
dc.contributor.authorPrasad, K.
dc.contributor.authorWong, H.
dc.contributor.authorOong, Z.
dc.contributor.authorCharnley, N.
dc.contributor.authorLaw, A.
dc.contributor.authorParikh, O.
dc.contributor.authorPillai, Manon
dc.contributor.authorWaddell, Thomas
dc.contributor.authorGriffiths, R.
dc.contributor.authorChow, S.
dc.date.accessioned2022-05-26T08:35:09Z
dc.date.available2022-05-26T08:35:09Z
dc.date.issued2022en
dc.identifier.citationHeseltine J, Allison J, Wong S, Prasad K, Wong H, Oong Z, et al. Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.. Vol. 40, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022. p. 335–335. en
dc.identifier.doi10.1200/JCO.2022.40.6_suppl.335en
dc.identifier.urihttp://hdl.handle.net/10541/625259
dc.description.abstractBackground: The TIVO-1 study demonstrated improved PFS in mRCC patients (pts) undergoing 1L treatment with T compared with sorafenib. We previously presented outcomes of our experience of T in 4 cancer centres in NWE. Here we present updated outcomes with longer follow-up (FU). Methods: mRCC pts commencing 1L T March 2017- May 2019 were identified. Outcomes of interest included overall response rate (ORR), survival (OS, PFS) and toxicity. Data cut off for this update was 30/11/2020. Results: 113 pts were identified with characteristics as in the table. Median FU was 25.9 mo (18.3-44.7mo), 18% pts remain on treatment at data cut-off. 88.5% commenced T at full dose, of which 67% maintained dose intensity. 11.5% commenced T with dose reduction due to prior TKI toxicities or comorbidities. Median number of cycles was 7 (1-33). In terms of efficacy, ORR was 29% (CR 0%, PR29%, SD39%, PD26%, NE 6%) and median PFS was 9.0 months (95% C.I. 6.0-12.1mo). Median PFS by IMDC risk group was: F= 23.0 months (95% C.I. 7.6-38.4mo); I= 10.0 months (95% C.I. 6.3-13.7mo); P= 3.0 months (95% C.I. 1.5.- 4.5mo), p value<0.0001. Median OS was 25.0 months (95% C.I. 15.4-34.6mo). Median OS by IMDC risk group was: F= NR with 72% alive at data cut-off; I= 26.0 months (95% C.I. 17.9-34.1mo); P= 7.0 months (95% C.I. 4.4-9.6mo), p value<0.0001. Adverse events (AEs) of any grade occurred in 77% (≥G3 13%) including fatigue 42% (≥G3 0%), diarrhoea 19% (≥G3 < 1%), mucositis 24% ( ≥G3 2%), anorexia 12% (≥G3 < 1%); and hypertension 7% (≥G3 2%). Notable ≥G3 events included abnormal liver function 3%; vascular events 2% and seizure < 1%. 18% of patients discontinued treatment due to toxicity with no treatment-related deaths. Conclusions: Our real world experience of 1L T suggests comparable activity with randomized data and other TKIs, particularly in F and I IMDC risk groups. The low incidence of serious AEs makes it an attractive option if unsuitable for combination therapies.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.6_suppl.335en
dc.titleTivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UKen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentClatterbridge Cancer Centre, Wirral,en
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record